214 related articles for article (PubMed ID: 38361033)
1. Multi-omic profiling of clear cell renal cell carcinoma identifies metabolic reprogramming associated with disease progression.
Hu J; Wang SG; Hou Y; Chen Z; Liu L; Li R; Li N; Zhou L; Yang Y; Wang L; Wang L; Yang X; Lei Y; Deng C; Li Y; Deng Z; Ding Y; Kuang Y; Yao Z; Xun Y; Li F; Li H; Hu J; Liu Z; Wang T; Hao Y; Jiao X; Guan W; Tao Z; Ren S; Chen K
Nat Genet; 2024 Mar; 56(3):442-457. PubMed ID: 38361033
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract][Full Text] [Related]
5. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
6. TFE3 gene rearrangement and protein expression contribute to a poor prognosis of renal cell carcinoma.
Lin J; Tang Z; Zhang C; Dong W; Liu Y; Huang H; Liu H; Huang J; Lin T; Chen X
Heliyon; 2023 May; 9(5):e16076. PubMed ID: 37215783
[TBL] [Abstract][Full Text] [Related]
7. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
[TBL] [Abstract][Full Text] [Related]
8. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
9. Screening and identification of prognostic genes associated with eosinophilic features of clear cell renal cell carcinoma.
Guo T; Jiang L; Wang T; Zhang J; Liu Y; Wang X; Zhang N; Chen S; Wang X
Heliyon; 2023 Jun; 9(6):e16479. PubMed ID: 37274638
[TBL] [Abstract][Full Text] [Related]
10. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma.
Jee B; Seo E; Park K; Kim YR; Byeon SJ; Lee SM; Chung JH; Song W; Sung HH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Lee HM; Park SH; Park WY; Kang M
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35625960
[TBL] [Abstract][Full Text] [Related]
12. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
13. MUC1 Tissue Expression and Its Soluble Form CA15-3 Identify a Clear Cell Renal Cell Carcinoma with Distinct Metabolic Profile and Poor Clinical Outcome.
Lucarelli G; Rutigliano M; Loizzo D; di Meo NA; Lasorsa F; Mastropasqua M; Maiorano E; Bizzoca C; Vincenti L; Battaglia M; Ditonno P
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430448
[TBL] [Abstract][Full Text] [Related]
14. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
[TBL] [Abstract][Full Text] [Related]
15. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
[TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analyses of A 12-metabolism-associated gene signature and its connection with tumor metastases in clear cell renal cell carcinoma.
Tan D; Miao D; Zhao C; Shi J; Lv Q; Xiong Z; Yang H; Zhang X
BMC Cancer; 2023 Mar; 23(1):264. PubMed ID: 36949462
[TBL] [Abstract][Full Text] [Related]
18. PYCR1 regulates glutamine metabolism to construct an immunosuppressive microenvironment for the progression of clear cell renal cell carcinoma.
Wei X; Zhang X; Wang S; Wang Y; Ji C; Yao L; Song N
Am J Cancer Res; 2022; 12(8):3780-3798. PubMed ID: 36119844
[TBL] [Abstract][Full Text] [Related]
19. POLD1 as a Prognostic Biomarker Correlated with Cell Proliferation and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Tian J; Cheng C; Gao J; Fu G; Xu Z; Chen X; Wu Y; Jin B
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047824
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
Front Immunol; 2022; 13():861328. PubMed ID: 35479084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
